|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 281, Issue 10, 6413-6427, March 10, 2006
AIFsh, a Novel Apoptosis-inducing Factor (AIF) Pro-apoptotic Isoform with Potential Pathological Relevance in Human Cancer* 1 2 3 4![]() ![]() ![]() 5
From the
AIF is a main mediator of caspase-independent cell death. It is encoded by a single gene located on chromosome X, region q2526 and A6 in humans and mice, respectively. Previous studies established that AIF codes for two isoforms of the protein, AIF and AIF-exB. Here, we identify a third AIF isoform resulting from an alternate transcriptional start site located at intron 9 of AIF. The resulting mRNA encodes a cytosolic protein that corresponds to the C-terminal domain of AIF (amino acids 353613). We named this new isoform AIFshort (AIFsh). AIFsh overexpression in HeLa cells results in nuclear translocation and caspase-independent cell death. Once in the nucleus, AIFsh provokes the same effects than AIF, namely chromatin condensation and large scale (50 kb) DNA fragmentation. In contrast, these apoptogenic effects are not precluded by the AIF-inhibiting protein Hsp70. These findings identify AIFsh as a new pro-apoptotic isoform of AIF, and also reveal that the first N-terminal 352 amino acids of AIF are not required for its apoptotic activity. In addition, we demonstrate that AIFsh is strongly down-regulated in tumor cells derived from kidney, vulva, skin, thyroid, and pancreas, whereas,
Received for publication, September 7, 2005 , and in revised form, December 15, 2005. The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) DQ016496 [GenBank] and DQ016497 [GenBank] . * This work was supported by the Association pour la Recherche sur le Cancer (contract N° 4812), Fondation de France, Fondation pour la Recherche Médicale, Ligue Nationale contre le Cancer, and the Pasteur-Weizmann Scientific Council (to S. A. S). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 Holds a postdoctoral fellowship from the Fondation de France. 2 Supported by a Marie Curie Intra-European fellowship within the 6th European Community Framework Programme (contract MEIF-2003-501887). 3 Supported by a Ph.D. fellowship from Fondation Hariri. 4 Supported by a Ph.D. fellowship from MENRT. 5 To whom correspondence should be addressed: Apoptose et Système Immunitaire, CNRS-URA 1961, Institut Pasteur, 25 rue du Dr. Roux, 75015 Paris, France. Tel.: 33-1-40-61-31-84; Fax: 33-1-40-61-31-86; E-mail: susin{at}pasteur.fr.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||